HMGA2 has been previously reported to act as a functional antagonist of PARP1 inhibitors in tumor cells [36], while DOT1L, a predictor of poor prognosis in most solid tumors, remains relatively understudied, with its role in PARP inhibitor-resistant OC still unidentified. Here, PARP1 is linked to neoplasm.